Form 4: CervoMed Director Receives Equity Grant

Director Marwan Sabbagh was granted options to purchase 8,150 shares of CervoMed common stock following his election to the board.

Summary

• Director Marwan Sabbagh received an option grant for 8,150 shares of CervoMed Inc. common stock.
• The grant was issued on June 8, 2026, following his election to the board of directors at the 2026 Annual Meeting.
• The options have an exercise price of $2.91 per share.
• The award vests in 1/12th increments monthly over one year, starting June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The options vest monthly over a one-year period, ending in mid-2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that standard equity grants for non-employee directors are common practice in the biotechnology sector to incentivize board members and align governance with long-term shareholder value.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with standard non-employee director compensation policies for small-cap biotech firms.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity-based compensation.

Next Steps

• Monthly vesting of options beginning June 30, 2026.

Key Dates

Keywords

CervoMed, CRVO, Form 4, Director Compensation, Equity Incentive Plan, Insider Transaction